PremiumThe FlyViking Therapeutics management to meet with B. Riley Viking Therapeutics Holds Annual Stockholders Meeting Viking Therapeutics put volume heavy and directionally bearish PremiumThe FlyViking Therapeutics initiated with an Overweight at Cantor Fitzgerald Viking Therapeutics price target lowered to $75 from $95 at Truist Viking Therapeutics participates in a conference call with Maxim Group PremiumCompany AnnouncementsViking Therapeutics Advances Clinical Pipeline in Q1 2025 Promising Developments and Financial Stability Underpin Buy Rating for Viking Therapeutics Viking Therapeutics reports Q1 EPS (41c), consensus (31c) 
